Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors.
St-Jacques R, Toulmond S, Auger A, Binkert C, Cromlish W, Fischli W, Harris J, Hess P, Jie Lan, Liu S, Riendeau D, Steiner B, Percival MD. St-Jacques R, et al. Among authors: binkert c. J Renin Angiotensin Aldosterone Syst. 2011 Sep;12(3):133-45. doi: 10.1177/1470320310392618. Epub 2011 Mar 10. J Renin Angiotensin Aldosterone Syst. 2011. PMID: 21393355 Free article.
New classes of potent and bioavailable human renin inhibitors.
Remen L, Bezençon O, Richard-Bildstein S, Bur D, Prade L, Corminboeuf O, Boss C, Grisostomi C, Sifferlen T, Strickner P, Hess P, Delahaye S, Treiber A, Weller T, Binkert C, Steiner B, Fischli W. Remen L, et al. Among authors: binkert c. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6762-5. doi: 10.1016/j.bmcl.2009.09.104. Epub 2009 Oct 1. Bioorg Med Chem Lett. 2009. PMID: 19853442
Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.
Bezençon O, Bur D, Weller T, Richard-Bildstein S, Remen L, Sifferlen T, Corminboeuf O, Grisostomi C, Boss C, Prade L, Delahaye S, Treiber A, Strickner P, Binkert C, Hess P, Steiner B, Fischli W. Bezençon O, et al. Among authors: binkert c. J Med Chem. 2009 Jun 25;52(12):3689-702. doi: 10.1021/jm900022f. J Med Chem. 2009. PMID: 19358611
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, Iglarz M, Meyer S, Rein J, Rey M, Treiber A, Clozel M, Fischli W, Weller T. Bolli MH, et al. Among authors: binkert c. J Med Chem. 2012 Sep 13;55(17):7849-61. doi: 10.1021/jm3009103. Epub 2012 Aug 16. J Med Chem. 2012. PMID: 22862294
Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.
Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W, Hess P, Mathys B, Morrison K, Müller C, Müller C, Nayler O, Qiu C, Rey M, Scherz MW, Velker J, Weller T, Xi JF, Ziltener P. Clozel M, et al. Among authors: binkert c. J Pharmacol Exp Ther. 2004 Oct;311(1):204-12. doi: 10.1124/jpet.104.068320. Epub 2004 May 14. J Pharmacol Exp Ther. 2004. PMID: 15146030
Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.
Bolli MH, Marfurt J, Grisostomi C, Boss C, Binkert C, Hess P, Treiber A, Thorin E, Morrison K, Buchmann S, Bur D, Ramuz H, Clozel M, Fischli W, Weller T. Bolli MH, et al. Among authors: binkert c. J Med Chem. 2004 May 20;47(11):2776-95. doi: 10.1021/jm031115r. J Med Chem. 2004. PMID: 15139756
196 results